ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1
    Publication Date: 1981-02-01
    Print ISSN: 0005-2795
    Electronic ISSN: 1879-2952
    Topics: Biology
    Published by Elsevier
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0827
    Keywords: Tumor ; Hypercalcemia ; Humoral ; Bone resorption
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Summary A transplantable nonmetastasizing Leydig cell tumor, which occurs spontaneously in the aged Fischer rat, was examined bothin vitro andin vivo. Animals carrying this tumor were found to have the syndrome recently called thehumoral hypercalcemia of malignancy, characterized by hypercalcemia, hypercalciuria, hypophosphatemia, renal phosphate wasting, increased urinary 3′5′-cyclic monophosphate (cyclic AMP) excretion, and suppressed circulating parathyroid hormone (PTH) concentrations. The changes in urinary cyclic adenosine monophosphate (cAMP) excretion occurred simultaneously with hypercalcemia in most animals. In one animal, the primary tumor was excised and this was followed by an immediate fall in serum calcium and urine cAMP excretion. Hypercalcemia was due to increased bone resorption. This was shown by bone histology, which demonstrated an increase in osteoclast number and activity on trabecular bone surfaces associated with bone loss in tumor-bearing animals. No tumor cells were seen adjacent to the osteoclasts. There was no evidence of metastatic disease as assessed by bone-seeking isotopes. Urinary hydroxyproline excretion was increased in tumor-bearing hypercalcemic animals, indicating an increase in bone turnover. The tumor cells were established in culture and found to produce a bone-resorbing factorin vitro using a bioassay for bone resorption based on the release of previously incorporated45Ca from fetal rat long bones in culture. This model of the humoral hypercalcemia of malignancy should make it possible to determine the nature of the boneresorbing factor produced by the cultured tumor cells which is responsible for the hypercalcemia, and the relationship of hypercalcemia and the production of the bone-resorbing factor to the other parameters of the syndrome, namely, renal phosphate wasting and increased urinary cAMP excretion.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0827
    Keywords: Dichloromethylene diphosphonate ; Hypercalcemia ; Rat tumor
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Summary There is a high frequency of Leydig cell tumors associated with hypercalcemia in the aged Fischer 344 rat. We studied a transplantable tumor cell line (Rice D-6) which is associated with hypercalcemia, hypercalciuria, hypophosphatemia, renal phosphate wasting, increased urinary cyclic adenosine monophosphate (AMP) excretion, absence of bone metastases, increased osteoclastic bone resorption, and suppressed immunoreactive parathyroid hormone (iPTH) concentrations. We examined the ability of dichloromethylene diphosphonate (Cl2MDP) to lower serum calcium and decrease the parameters of increased bone resorption. We used this drug also as a pharmacologic tool to determine the relationship of hypercalcemia and increased bone resorption to the abnormalities in renal tubular function associated with the humoral hypercalcemia of malignancy. Daily administration of Cl2MDP before development of hypercalcemia, in doses from 2.5–40 mg/kg body weight subcutaneously, delayed and suppressed both the hypercalcemia and hypercalciuria. There was an increase in bone mass and decrease in both osteoclast number and activity compared with bones from untreated tumor-bearing animals. The urinary hydroxyproline excretion in treated animals declined towards the normal range. There were no significant effects on serum phosphorus, urine phosphorus, or urine cyclic AMP excretion. These data suggest that Cl2MDP reverses the increased bone resorption that occurs in the humoral hypercalcemia of malignancy, and confirms that diphosphonates are effective agents in the prevention and treatment of increased bone resorption associated with malignant disease. They also suggest that renal phosphate wasting and increased urinary cyclic AMP excretion are not directly related to the hypercalcemia.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...